Home > Riviste > Minerva Urologica e Nefrologica > Fascicoli precedenti > Minerva Urologica e Nefrologica 2017 August;69(4) > Minerva Urologica e Nefrologica 2017 August;69(4):342-8

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA UROLOGICA E NEFROLOGICA

Rivista di Nefrologia e Urologia


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984


eTOC

 

ORIGINAL ARTICLE  


Minerva Urologica e Nefrologica 2017 August;69(4):342-8

DOI: 10.23736/S0393-2249.16.02690-4

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Can we predict chemotherapy response in patients with metastatic testicular cancer? Role of thrombocytosis as a novel marker

Mehmet I. GOKCE , Murat MERMERKAYA, Evren SÜER, Faraj AFANDIYEV, Sümer BALTACI

Department of Urology, Ankara University School of Medicine, Ankara, Turkey


PDF  


BACKGROUND: Primary treatment of choice for advanced germ cell tumors is 3 to 4 cycles of combination bleomycin-etoposide-cisplatin (BEP) chemotherapy. Although most patients treated for advanced germ cell tumors (GCT) will be cured, approximately 30% will fail to achieve a durable complete response (CR). Thrombocytosis has been found to be related with significantly shorter survival in many cancers. However, its role in testicular cancer patients has not been studied previously. The objective of this study was to investigate the relationship between thrombocytosis and chemotherapy response in patients with metastatic testicular cancer.
METHODS: Records of 113 patients with advanced stage testicular cancer were reviewed. Treatment outcomes were classified as complete clinical response (cCR), partial clinical response (pCR), complete pathological response (cPR) and treatment failure and the relationship with thrombocytosis was investigated. Logistic regression analysis was performed to identify factors associated with treatment failure.
RESULTS: Totally 103 patients met the eligibility criteria. Thrombocytosis was detected in 26 (25.2%) patients. Treatment failure was observed in 14 (53.8%) and 28 (36.4%) of the patients in the thrombocytosis and non-thrombocytosis groups respectively (P=0.037). Thrombocytosis and IGCCCG high-risk group are found as independent prognostic factors for treatment failure in multivariate analysis.
CONCLUSIONS: Thrombocytosis is seen in 25% of patients with testicular GCT and it is found to be associated with poorer chemotherapy response in metastatic patients. It can be used to predict the response to chemotherapy.


KEY WORDS: Testicular neoplasms - Germ cell and embryonal neoplasms - Drug therapy - Thrombocytosis

inizio pagina

Publication History

Issue published online: June 9, 2017
Article first published online: October 12, 2016
Manuscript accepted: October 7, 2016
Manuscript revised: September 20, 2016
Manuscript received: March 25, 2016

Per citare questo articolo

Gokce MI, Mermerkaya M, Süer E, Afandiyev F, Baltacı S. Can we predict chemotherapy response in patients with metastatic testicular cancer? Role of thrombocytosis as a novel marker. Minerva Urol Nefrol 2017;69:342-8. DOI: 10.23736/S0393-2249.16.02690-4

Corresponding author e-mail

migokce@ankara.edu.tr